<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital syphilis: Management and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital syphilis: Management and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital syphilis: Management and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonio C Arrieta, MD, FIDSA, FPIDS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12404245"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital syphilis occurs when the spirochete <em>Treponema pallidum</em> is transmitted transplacentally from a pregnant individual to the fetus or, occasionally, through direct contact with infectious lesions during birth. Infection can result in stillbirth, prematurity, or a wide spectrum of clinical manifestations; only severe cases are clinically apparent at birth [<a href="#rid1">1</a>].</p><p>The management and outcome of congenital syphilis will be discussed here. The clinical features, evaluation, and diagnosis of congenital syphilis; syphilis in pregnancy; and acquired syphilis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p></p><p class="headingAnchor" id="H1244911449"><span class="h1">LIKELIHOOD OF INFECTION</span><span class="headingEndMark"> — </span>The diagnosis of congenital syphilis should be suspected in all infants whose mothers have reactive nontreponemal and treponemal tests for syphilis. (See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Clinical suspicion'</a>.)</p><p>To maximize treatment of children potentially infected with <em>T. pallidum</em>, the American Academy of Pediatrics (AAP) categorizes congenital syphilis infection in the neonate as "proven or highly probable," "possible," "less likely," and "unlikely" based upon identification of spirochetes in tissue or body fluids, maternal and infant serologies, maternal treatment history, and the neonate's clinical findings  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a>). The diagnostic evaluation and approach to determining the likelihood of infection are summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p>The categories of "possible" and "less likely" include infants with normal physical examination and serological results not meeting diagnostic criteria but who nevertheless are still at risk of congenital syphilis. The inclusion of these at-risk infants helps to ensure that all possible cases are treated; however, not all at-risk infants are truly infected [<a href="#rid2">2</a>].</p><p>The vagaries of the maternal history of syphilis, inconsistent physical findings in the newborn, and challenges of interpreting serologic tests in combination with the potential consequences of delayed or missed diagnosis of congenital syphilis demand a "safety first" approach to both diagnosis and treatment [<a href="#rid3">3,4</a>]. Our suggested approach described in the following sections is generally consistent with guidelines of the United States Centers for Disease Control and Prevention (CDC) and the AAP [<a href="#rid5">5,6</a>]. Similar guidance is provided by the World Health Organization [<a href="#rid7">7</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H21000446"><span class="h1">TREATMENT ACCORDING TO DIAGNOSTIC CATEGORY</span><span class="headingEndMark"> — </span>The following sections outline the approach to determining appropriate treatment based upon likelihood of infection  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>). Additional details about penicillin therapy are provided below. (See <a class="local">'Penicillin therapy'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proven or highly probable disease</strong> – For neonates with proven or highly probable congenital syphilis, we recommend a 10-day course of intravenous (IV) aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a>  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) [<a href="#rid5">5,6</a>]. (See <a class="local">'10-day regimen'</a> below.)</p><p></p><p class="bulletIndent1">To prevent long-term morbidity, all neonates with proven or highly probable syphilis are treated for presumed central nervous system syphilis. Although cerebrospinal fluid (CSF) results do not alter the treatment, examination of the CSF is necessary since it may inform prognosis and subsequent follow-up. (See <a class="local">'Follow-up evaluations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible congenital syphilis</strong> – Treatment of neonates with possible congenital syphilis is as follows  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) [<a href="#rid5">5,6</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonates at higher risk</strong> – Neonates in the "possible" category who have a higher risk of infection (ie, maternal risk of untreated syphilis is high <strong>or</strong> neonate's nontreponemal titer is reactive) should undergo additional evaluation to assess the extent (if any) of organ involvement. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation for extent of organ involvement'</a>.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Any abnormality on evaluation</strong> – If there are any abnormalities on the evaluation (eg, reactive CSF Venereal Disease Research Laboratory [VDRL], CSF pleocytosis, elevated CSF protein, bony abnormalities), we recommend treatment with IV aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> for 10 days. (See <a class="local">'10-day regimen'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No abnormalities on evaluation</strong> – If the results of the evaluation are normal and follow-up of the infant is assured, we suggest a single intramuscular (IM) dose of long-acting penicillin (ie, <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a>). This approach requires that all components of the evaluation have been completed and results are normal. Treatment failures with single-dose therapy have been reported among infants who had incomplete evaluation [<a href="#rid8">8,9</a>]. The frequency of such treatment failures is unknown but appears to be low. (See <a class="local">'Single-dose regimen'</a> below.)</p><p></p><p class="bulletIndent3">If evaluation is not performed or is not interpretable (traumatic lumbar puncture) or if follow-up cannot be assured, we suggest a 10-day course of IV aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a>. (See <a class="local">'10-day regimen'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonates at lower risk </strong>– Neonates in the "possible" category who have a lower risk of infection (ie, maternal risk of untreated syphilis is low <strong>and </strong>neonate's nontreponemal titer is nonreactive) do not require additional evaluation. For these neonates, we suggest a single IM dose of long-acting penicillin (ie, <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a>) [<a href="#rid10">10</a>]. (See <a class="local">'Single-dose regimen'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital syphilis less likely </strong>– For neonates in this category, further evaluation is not necessary. We suggest a single IM dose of <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a>  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) [<a href="#rid5">5,6</a>]. (See <a class="local">'Single-dose regimen'</a> below.) </p><p></p><p class="bulletIndent1">The rationale for treatment in this setting is that infection of the fetus may occur despite appropriate maternal therapy during pregnancy. The reported failure rates of maternal treatment to prevent congenital infection range from 2 to 14 percent [<a href="#rid11">11-14</a>]; higher rates are more frequent in mothers with secondary syphilis. Treating the neonate at birth may prevent the development of clinical disease if maternal therapy during pregnancy did not prevent fetal infection [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1">Alternatively, some specialists opt not to treat such infants if close follow-up is certain (see <a class="local">'Follow-up serology'</a> below). If the infant's titers do not decline as expected for transplacentally acquired antibody, treatment should be provided. (See <a class="local">'&gt;1 month of age'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital syphilis unlikely </strong>– Newborns in this category do <strong>not</strong> require treatment or further evaluation  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) [<a href="#rid5">5,6</a>]. However, if follow-up is uncertain, some experts would provide a single IM dose of <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> to protect the infant in the unlikely event that the mother was reinfected. (See <a class="local">'Single-dose regimen'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants and children &gt;1 month of age </strong>– Children who are diagnosed with congenital syphilis after one month of age (including those with previously untreated late congenital syphilis) require parenteral penicillin therapy, as discussed below. (See <a class="local">'&gt;1 month of age'</a> below.)</p><p></p><p class="headingAnchor" id="H21001146"><span class="h1">PENICILLIN THERAPY</span><span class="headingEndMark"> — </span>Parenteral penicillin is the drug of choice for the treatment of congenital syphilis for the following reasons [<a href="#rid5">5,6</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Penicillin is the only drug with documented efficacy. </p><p class="bulletIndent1"><span class="glyph">●</span>It has minimal toxicity. </p><p class="bulletIndent1"><span class="glyph">●</span><em>T. pallidum</em> is extremely sensitive to penicillin, as demonstrated in animal studies [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>There is no evidence of increasing spirochete resistance to penicillin, but such evidence would come only from the recognition of therapeutic failures.</p><p></p><p>The minimal inhibitory concentration (MIC) for penicillin is approximately 0.0005 mcg/mL [<a href="#rid17">17</a>]. Effective treatment of neurosyphilis requires maintaining a concentration of 0.018 mcg/mL in the cerebrospinal fluid (CSF) for 7 to 10 days [<a href="#rid18">18</a>]. Current regimens are designed to achieve and maintain several times the necessary MIC and to avoid penicillin-free intervals during therapy.</p><p class="headingAnchor" id="H21002590"><span class="h2">&lt;1 month of age</span></p><p class="headingAnchor" id="H21001153"><span class="h3">Single-dose regimen</span><span class="headingEndMark"> — </span>For the single-dose regimen, long-acting intramuscular (IM) <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> is used. </p><p>Dosing is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">Penicillin G benzathine</a> 50,000 units/kg given IM as a single dose</p><p></p><p>Two randomized trials have evaluated the efficacy of single-dose penicillin therapy in preventing/treating congenital syphilis in asymptomatic infants born to mothers with no treatment or inadequate/suboptimal treatment for syphilis during pregnancy [<a href="#rid15">15,16</a>]. One trial compared single-dose <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> with no therapy in asymptomatic infants at high risk of congenital syphilis (untreated mothers with Venereal Disease Research Laboratory test [VDRL] ≥1:32) [<a href="#rid15">15</a>]. None of 11 infants in the treatment group developed congenital syphilis, compared with four of eight infants who were not treated [<a href="#rid15">15</a>]. In the second trial, 169 asymptomatic neonates (normal physical examination, normal CSF evaluation, normal long-bone radiographs, and no visceral abnormalities) were randomly assigned to treatment with a single dose of IM benzathine penicillin or 10 days of parenteral <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> [<a href="#rid16">16</a>]. There were no treatment failures in either group.</p><p class="headingAnchor" id="H21001160"><span class="h3">10-day regimen</span><span class="headingEndMark"> — </span>The 10-day penicillin regimen is given intravenously (IV) with aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> 50,000 units/kg IV every 12 hours (for neonates ≤7 days of age) or every 8 hours (for neonates &gt;7 days of age) for a total of 10 days </p><p></p><p>An alternative option for infants without IV access is to treat with daily IM injections of <a class="drug drug_pediatric" data-topicid="12688" href="/d/drug information/12688.html" rel="external">penicillin G procaine</a> (intermediate-acting penicillin). However, procaine penicillin is no longer available in the United States and many other parts of the world. </p><p>If the newborn received antibiotics other than penicillin for other reasons (eg, neonates undergoing evaluation for possible early-onset sepsis), this does <strong>not</strong> change the required treatment for congenital syphilis. A full 10-day course of penicillin should still be administered [<a href="#rid5">5,6</a>]. If more than one day of penicillin therapy is missed, the entire course should be restarted. (See <a class="local">'Missed doses'</a> below.)</p><p class="headingAnchor" id="H21003096"><span class="h2">&gt;1 month of age</span><span class="headingEndMark"> — </span>For infants and children diagnosed with syphilis after one month of age, including those with late congenital syphilis and children with acquired syphilis, treatment is as follows [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic patients </strong>– Patients with clinical or radiologic findings consistent congenital syphilis are treated with a 10-day course of aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> (50,000 units/kg IV every four to six hours). If it is likely that the infection has been present for &gt;1 year (eg, children with late congenital syphilis who are diagnosed after infancy), we suggest providing a single dose of IM <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> (50,000 units/kg) after completion of the 10-day IV course [<a href="#rid5">5</a>]. The rationale for the additional dose of long-acting IM benzathine penicillin in this setting is that the 10-day treatment course may not be sufficient to treat late syphilis. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Preferred regimens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients</strong> – For infants and children with positive syphilis serology but without any clinical or radiologic manifestations of disease and with normal CSF studies, we suggest treatment with three weekly doses of long-acting IM <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> (50,000 units/kg) [<a href="#rid5">5,6</a>]. The treatment regimen should not exceed the adult regimen. A shorter treatment course (ie, one or two doses of IM penicillin G benzathine) can be considered if late syphilis is unlikely (eg, infants with congenital syphilis who are diagnosed within the first year of life) [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Late latent syphilis'</a>.)</p><p></p><p class="headingAnchor" id="H21002576"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">Penicillin G</a> is generally safe and well tolerated in newborns. Potential adverse effects include local reactions at the injection site and the possibility of a rare adverse reaction (the Jarisch-Herxheimer reaction). The Jarisch-Herxheimer is characterized by onset of fever 2 to 12 hours after initiation of therapy for active syphilis [<a href="#rid19">19</a>]. Rarely, cardiovascular collapse, seizures, and death also have been reported [<a href="#rid20">20</a>]. The Jarisch-Herxheimer reaction is thought to be produced by the release of endotoxin-like compounds during penicillin-mediated lysis of <em>T. pallidum</em>. It is rare in newborns but can occur in older infants and children. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Jarisch-Herxheimer reaction'</a>.)</p><p class="headingAnchor" id="H21001167"><span class="h2">Special circumstances</span></p><p class="headingAnchor" id="H284805075"><span class="h3">Missed doses</span><span class="headingEndMark"> — </span>If more than one day of penicillin therapy is missed, the entire course should be restarted [<a href="#rid5">5,6</a>]. Effective treatment of neurosyphilis requires maintaining a concentration of 0.018 mcg/mL of penicillin in CSF for 7 to 10 days. (See <a class="local">'Penicillin therapy'</a> above.)</p><p class="headingAnchor" id="H21001174"><span class="h3">Penicillin allergy</span><span class="headingEndMark"> — </span>Penicillin is the treatment of choice for congenital syphilis. There are insufficient data regarding the adequacy of treatment with agents other than penicillins (eg, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>). For the infant/child who requires treatment for syphilis but has a penicillin allergy or develops an allergic reaction that is presumed to be due to penicillin, the United States Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend desensitization and then treatment with penicillin [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions", section on 'Desensitization'</a>.) </p><p>If a nonpenicillin agent is used, close serologic and CSF follow-up are necessary. (See <a class="local">'Follow-up evaluations'</a> below.)</p><p class="headingAnchor" id="H21001188"><span class="h3">Maternal coinfection with HIV</span><span class="headingEndMark"> — </span>Infants born to mothers who are coinfected with syphilis and human immunodeficiency virus (HIV) should receive the same evaluation and treatment for syphilis as those whose mothers do not have HIV infection [<a href="#rid5">5</a>]. There is insufficient evidence to determine whether such infants require different evaluation, treatment, or follow-up. Evaluation and management of infants born to mothers with HIV are discussed separately. (See  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months"</a> and  <a class="medical medical_review" href="/d/html/126417.html" rel="external">"Intrapartum and postpartum management of pregnant women with HIV and infant prophylaxis in resource-rich settings", section on 'Infant prophylaxis'</a>.) </p><p class="headingAnchor" id="H3146933"><span class="h1">FOLLOW-UP EVALUATIONS</span><span class="headingEndMark"> — </span>Infants who were treated should be monitored to assure adequate treatment response. Follow-up evaluations are warranted for all infants and children who have reactive serologic tests for syphilis and/or were born to mothers who were seroreactive at delivery [<a href="#rid5">5,6,21-23</a>].</p><p class="headingAnchor" id="H284805145"><span class="h2">Examination</span><span class="headingEndMark"> — </span>During regularly scheduled well-child care visits, the clinician should carefully assess for manifestations of congenital syphilis during the first year (for manifestations of early congenital syphilis)  (<a class="graphic graphic_table graphicRef67809" href="/d/graphic/67809.html" rel="external">table 2</a>) and beyond (for manifestations of late congenital syphilis)  (<a class="graphic graphic_table graphicRef81529" href="/d/graphic/81529.html" rel="external">table 3</a>) [<a href="#rid5">5,6</a>]. </p><p class="headingAnchor" id="H1805348137"><span class="h2">Developmental surveillance and sensory screening</span><span class="headingEndMark"> — </span>Routine surveillance should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Yearly hearing evaluation (see  <a class="medical medical_review" href="/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Yearly vision screening and eye examination (see  <a class="medical medical_review" href="/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Serial developmental assessments throughout infancy and childhood to ensure that the infant is reaching expected developmental milestones (see  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a>)</p><p></p><p>In one study, children born to mothers with reactive syphilis serology during pregnancy were at increased risk of neurodevelopmental impairment or speech delays regardless of whether they were infected [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H21003182"><span class="h2">Follow-up serology</span><span class="headingEndMark"> — </span>Reactive serology in the newborn does not differentiate between the newborn's antibody response to infection and transplacentally acquired maternal antibody. Serial monitoring of the infant's serology is necessary for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>In infants treated with penicillin, serial monitoring is necessary to ensure an appropriate treatment response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In untreated infants (ie, those in the "unlikely congenital syphilis" category), serial monitoring is necessary to definitively exclude congenital syphilis.</p><p></p><p>Thus, <strong>all</strong> infants born to mothers with syphilis require follow-up serologic monitoring, regardless of whether the infant was seropositive or seronegative at birth and regardless of whether the infant was treated with penicillin.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of testing</strong> – Follow-up serologic testing should be performed every two to three months. Serology should be repeated until the test becomes nonreactive or the titer has decreased fourfold (equivalent to two dilutions) [<a href="#rid5">5,25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests to perform</strong> – Follow-up serologic monitoring should be performed with nontreponemal tests (ie, quantitative Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR] titers). Ideally, follow-up testing should be performed with the same test as was used in the newborn period. Additional details about these tests are provided separately. (See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Nontreponemal tests'</a>.) </p><p></p><p class="bulletIndent1">Treponemal tests should <strong>not</strong> be used to evaluate treatment response because they can remain positive despite effective treatment [<a href="#rid5">5,27</a>].</p><p></p><p class="bulletIndent1">However, in instances when the diagnosis is uncertain, treponemal tests can be used later in infancy or childhood to help establish the diagnosis of congenital syphilis. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Treponemal tests'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expected response</strong> – The infant's VDRL or RPR titers should decline by three months of age and be nonreactive by six months of age if the infant was successfully treated or not infected (ie, if the initial reactive test in the newborn period was due to passive transfer of maternal immunoglobulin G [IgG] antibody) [<a href="#rid5">5,28,29</a>]. The response may be slower in infants and children treated after one month of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment failure</strong> – Treatment failure, or failure of maternal treatment to prevent congenital syphilis, is indicated by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Failure of the VDRL or RPR titers to decline, or</p><p class="bulletIndent2"><span class="glyph">•</span>Increase in the VDRL or RPR after 6 to 12 months of age (or 6 to 12 months after completing treatment in children treated after the neonatal period)</p><p></p><p class="bulletIndent1">In such circumstances, the infant/child should undergo a lumbar puncture (LP) to obtain cerebrospinal fluid (CSF) for VDRL, cell count, and protein, and be treated with an extended course of parenteral penicillin, even if the infant/child was treated previously [<a href="#rid5">5,6</a>]. (See <a class="local">'&gt;1 month of age'</a> above and  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Lumbar puncture'</a>.)</p><p></p><p class="headingAnchor" id="H21003190"><span class="h2">Cerebrospinal fluid evaluation</span><span class="headingEndMark"> — </span>Repeat CSF evaluations are generally <strong>not</strong> necessary unless the infant has persistently positive nontreponemal titers at 6 to 12 months [<a href="#rid6">6</a>].</p><p>If repeat LP is performed and is abnormal (ie, reactive CSF VDRL or abnormal CSF white blood cell count or protein that cannot be attributed to other ongoing illnesses), the infant should be retreated with an extended course of parenteral penicillin therapy [<a href="#rid5">5,6</a>]. (See <a class="local">'&gt;1 month of age'</a> above.) </p><p>Neuroimaging studies may be warranted in children with persistently reactive CSF VDRL, elevated CSF cell count, and/or elevated CSF protein [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H13027163"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>In the United States, the case fatality rate for congenital syphilis is between 6 and 8 percent [<a href="#rid30">30,31</a>]. Approximately 90 percent of fatal cases are associated with lack of prenatal care or inadequate prenatal care.</p><p>Appropriate treatment of early congenital syphilis within the first three months after birth prevents some, but not all, of the late manifestations of congenital syphilis [<a href="#rid29">29,32,33</a>]. Interstitial keratitis  (<a class="graphic graphic_picture graphicRef52740" href="/d/graphic/52740.html" rel="external">picture 1</a>) and anterior tibial bowing ("saber shins")  (<a class="graphic graphic_picture graphicRef81604" href="/d/graphic/81604.html" rel="external">picture 2</a>) may occur or progress despite appropriate therapy [<a href="#rid34">34</a>].</p><p>Syphilis infection may persist for life. Treponemes appear to persist in extracellular loci with little or no inflammatory response elicited. A history of syphilis or treatment for syphilis provides relatively minor and unreliable protection against subsequent infection [<a href="#rid35">35</a>]. Active disease after reinfection is common, regardless of nontreponemal antibody reactivity.</p><p class="headingAnchor" id="H3146940"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Measures to prevent congenital syphilis include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening during pregnancy</strong> – Most cases of congenital syphilis are preventable with routine prenatal care, screening for syphilis in pregnant individuals, penicillin treatment of infected individuals and their sexual partners, and appropriate monitoring and interpretation of treatment response [<a href="#rid14">14,36-41</a>]. Screening and treatment of syphilis during pregnancy are discussed separately. (See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy", section on 'Maternal screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>International adoptees</strong> – Syphilis testing is recommended as part of the evaluation of internationally adopted children, as discussed separately. (See  <a class="medical medical_review" href="/d/html/16709.html" rel="external">"International adoption: Infectious disease aspects", section on 'Syphilis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control measures</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Standard precautions</strong> – Standard precautions are recommended for infants with suspected or proven congenital syphilis [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Standard precautions'</a>.) </p><p></p><p class="bulletIndent2">In addition, gloves should be worn when caring for infants with skin or mucous membrane lesions until 24 hours of treatment have been completed [<a href="#rid42">42</a>]. Moist open lesions, secretions, and body fluids (eg, cerebrospinal fluid [CSF], blood) contain spirochetes and are infectious [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Gloves'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of exposures</strong> – Persons, including hospital personnel, who had close unprotected contact with an infant or child with active early syphilis before the patient was diagnosed or during the first 24 hours of treatment should be examined for syphilitic lesions (ie, chancre) two to three weeks after contact [<a href="#rid6">6</a>]. Serologic testing should be performed and repeated three months after exposure, or sooner if symptoms develop. Immediate treatment (<a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> 50,000 units/kg intramuscularly as a single dose; maximum dose 2.4 million units) may be warranted if the degree of exposure was substantial.</p><p></p><p>In 2007, the World Health Organization launched an initiative to eliminate congenital syphilis that set targets of at least 90 percent of pregnant women being tested for syphilis and at least 90 percent of seropositive pregnant women receiving adequate treatment by 2015 [<a href="#rid43">43</a>]. Considerable progress has been made toward these goals, particularly with regards to [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing access to maternal and newborn services</p><p class="bulletIndent1"><span class="glyph">●</span>Screening and treating pregnant women and their partners</p><p class="bulletIndent1"><span class="glyph">●</span>Establishing surveillance, monitoring, and evaluation systems</p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring advocacy and sustained political commitment</p><p></p><p>Linking the efforts for global elimination of congenital syphilis to an integrated strategy of eliminating mother-to-child HIV transmission affords the opportunity of synergistic benefits. In a 2015 report that included data from 58 countries, the median proportion of pregnant women receiving at least one antenatal care visit was 90 percent, and there were notable successes in declaring some countries free of mother-to-child transmission of syphilis [<a href="#rid45">45</a>].</p><p>Prevention of acquired syphilis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Treatment after an exposure'</a> and  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H1817607474"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_society_guidelines" href="/d/html/111578.html" rel="external">"Society guideline links: TORCH infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_society_guidelines" href="/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p></p><p class="headingAnchor" id="H180673387"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83398.html" rel="external">"Patient education: Congenital syphilis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12404253"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Likelihood of infection</strong> – The vagaries of the maternal history of syphilis and signs or lack of signs in the newborn in combination with the potential consequences of delayed or missed diagnosis of congenital syphilis demand a "safety first" approach to diagnosis and treatment. Congenital syphilis should be suspected in all newborn infants whose mothers have reactive nontreponemal and treponemal tests for syphilis. The diagnostic evaluation and approach to determining the likelihood of infection are summarized in the table and figure  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Penicillin is the treatment of choice for congenital syphilis. The treatment regimen depends on the likelihood of infection  (<a class="graphic graphic_table graphicRef140142" href="/d/graphic/140142.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef140138" href="/d/graphic/140138.html" rel="external">algorithm 1</a>) (see <a class="local">'Treatment according to diagnostic category'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Proven or highly probable disease</strong> – For neonates in this category, we recommend an extended course of penicillin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). These neonates are presumed to have central nervous system syphilis. Treatment consists of aqueous crystalline <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> 50,000 units/kg intravenously (IV) every 12 hours (for infants ≤7 days of age) or every 8 hours (for infants &gt;7 days of age) for a total of 10 days. (See <a class="local">'10-day regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Possible congenital syphilis</strong> – For neonates in this category who have reactive nontreponemal serologies and any abnormality on additional diagnostic evaluation (eg, reactive cerebrospinal fluid [CSF], Venereal Disease Research Laboratory [VDRL], CSF pleocytosis, elevated CSF protein, bony abnormalities), we recommend a 10-day of penicillin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Treatment is the same as for newborns with proven or highly probable congenital syphilis. (See <a class="local">'10-day regimen'</a> above.)</p><p></p><p class="bulletIndent2">For neonates in this category who have reactive nontreponemal serologies and no other abnormalities on evaluation and those with nonreactive nontreponemal serologies, we suggest a single intramuscular (IM) dose of long-acting penicillin rather than an extended treatment course (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Treatment consists of <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> 50,000 units/kg given as a single IM dose. (See <a class="local">'Single-dose regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital syphilis less likely </strong>– For neonates in this category, we suggest a single dose of IM <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">benzathine penicillin</a> G rather than an extended treatment course or no treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Single-dose regimen'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital syphilis unlikely </strong>– Neonates in this category generally do <strong>not</strong> require treatment. However, some experts would provide a single IM dose of <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> if follow-up is uncertain. (See <a class="local">'Single-dose regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late diagnosis</strong> – For symptomatic infants and children diagnosed with syphilis after one month of age, we suggest an extended treatment course rather than single-dose therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For asymptomatic children, we suggest three weekly doses of IM <a class="drug drug_pediatric" data-topicid="12686" href="/d/drug information/12686.html" rel="external">penicillin G benzathine</a> rather than other regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'&gt;1 month of age'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Follow-up evaluations are warranted for all infants and children who have reactive serologic tests for syphilis and/or were born to mothers who were seroreactive at delivery. Follow-up includes (see <a class="local">'Follow-up evaluations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination to assess for manifestations of congenital syphilis. (See <a class="local">'Examination'</a> above and  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Yearly hearing evaluation. (See  <a class="medical medical_review" href="/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Yearly vision screening and eye examination. (See  <a class="medical medical_review" href="/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serial developmental assessments throughout infancy and childhood to ensure that the infant is reaching expected developmental milestones. (See  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Follow-up serologic testing with nontreponemal tests (ie, quantitative VDRL or rapid plasma reagin [RPR]) performed every two to three months until the test becomes nonreactive or the titer has decreased fourfold. (See <a class="local">'Follow-up serology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Follow-up lumbar puncture (LP) is warranted only if the infant has persistently positive nontreponemal titers at 6 to 12 months. (See <a class="local">'Cerebrospinal fluid evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment failure</strong> – Treatment failure, or failure of maternal treatment to prevent congenital syphilis, is indicated by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Failure of the VDRL or RPR titers to decline, or</p><p class="bulletIndent2"><span class="glyph">•</span>Increase in the VDRL or RPR after 6 to 12 months of age (or 6 to 12 months after completing treatment in children treated after the neonatal period)</p><p></p><p class="bulletIndent1">In such circumstances, the infant/child should undergo a full evaluation (including LP) and should be treated with an extended course of penicillin. (See <a class="local">'Follow-up serology'</a> above and <a class="local">'&gt;1 month of age'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – The case fatality rate for congenital syphilis is between 6 and 8 percent. Appropriate treatment of early congenital syphilis within the first three months after birth prevents some, but not all, of the late manifestations of congenital syphilis. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="headingAnchor" id="H3042620336"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Simon R Dobson, MD, FRCP(C), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevention. Syphilis (Treponema pallidum) 2018 Case Definition. https://ndc.services.cdc.gov/case-definitions/syphilis-2018/ (Accessed on June 17, 2021).</li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li class="breakAll">Dobson SR, Sanchez PJ. Syphilis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th Ed, Cherry JD, Harrison GJ, Kaplan SL, Steinbach, WJ, Hotez, PJ (Eds), Elsevier, Philadelphia, PA 2019. p.1268.</li><li><a class="nounderline abstract_t">Kimball A, Torrone E, Miele K, et al. Missed Opportunities for Prevention of Congenital Syphilis - United States, 2018. MMWR Morb Mortal Wkly Rep 2020; 69:661.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</a></li><li class="breakAll">American Academy of Pediatrics. Syphilis. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.729.</li><li class="breakAll">WHO guidelines for the treatment of Treponema pallidum (syphilis). 2016. Available at: http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf?ua=1 (Accessed on September 15, 2016).</li><li><a class="nounderline abstract_t">Beck-Sague C, Alexander ER. Failure of benzathine penicillin G treatment in early congenital syphilis. Pediatr Infect Dis J 1987; 6:1061.</a></li><li><a class="nounderline abstract_t">Woolf A, Wilfert CM, Kelsey DB. Childhood syphilis in North Carolina. N C Med J 1980; 41:443.</a></li><li><a class="nounderline abstract_t">Wozniak PS, Cantey JB, Zeray F, et al. Congenital syphilis in neonates with nonreactive nontreponemal test results. J Perinatol 2017; 37:1112.</a></li><li><a class="nounderline abstract_t">Alexander JM, Sheffield JS, Sanchez PJ, et al. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol 1999; 93:5.</a></li><li><a class="nounderline abstract_t">Conover CS, Rend CA, Miller GB Jr, Schmid GP. Congenital syphilis after treatment of maternal syphilis with a penicillin regimen exceeding CDC guidelines. Infect Dis Obstet Gynecol 1998; 6:134.</a></li><li><a class="nounderline abstract_t">Sheffield JS, Sánchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol 2002; 186:569.</a></li><li><a class="nounderline abstract_t">McFarlin BL, Bottoms SF, Dock BS, Isada NB. Epidemic syphilis: maternal factors associated with congenital infection. Am J Obstet Gynecol 1994; 170:535.</a></li><li><a class="nounderline abstract_t">Radcliffe M, Meyer M, Roditi D, Malan A. Single-dose benzathine penicillin in infants at risk of congenital syphilis--results of a randomised study. S Afr Med J 1997; 87:62.</a></li><li><a class="nounderline abstract_t">Paryani SG, Vaughn AJ, Crosby M, Lawrence S. Treatment of asymptomatic congenital syphilis: benzathine versus procaine penicillin G therapy. J Pediatr 1994; 125:471.</a></li><li><a class="nounderline abstract_t">Norris SJ, Edmondson DG. In vitro culture system to determine MICs and MBCs of antimicrobial agents against Treponema pallidum subsp. pallidum (Nichols strain). Antimicrob Agents Chemother 1988; 32:68.</a></li><li><a class="nounderline abstract_t">Tramont EC. Persistence of Treponema pallidum following penicillin G therapy. Report of two cases. JAMA 1976; 236:2206.</a></li><li><a class="nounderline abstract_t">Woods CR. Syphilis in children: congenital and acquired. Semin Pediatr Infect Dis 2005; 16:245.</a></li><li><a class="nounderline abstract_t">HOLZEL A. Jarisch-Herxheimer reaction following penicillin treatment of early congenital syphilis. Br J Vener Dis 1956; 32:175.</a></li><li class="breakAll">Kollmann TR, Dobson S. Syphilis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.524.</li><li><a class="nounderline abstract_t">Ikeda MK, Jenson HB. Evaluation and treatment of congenital syphilis. J Pediatr 1990; 117:843.</a></li><li><a class="nounderline abstract_t">Rathbun KC. Congenital syphilis: a proposal for improved surveillance, diagnosis, and treatment. Sex Transm Dis 1983; 10:102.</a></li><li><a class="nounderline abstract_t">Verghese VP, Hendson L, Singh A, et al. Early Childhood Neurodevelopmental Outcomes in Infants Exposed to Infectious Syphilis In Utero. Pediatr Infect Dis J 2018; 37:576.</a></li><li><a class="nounderline abstract_t">Hardy JB, Hardy PH, Oppenheimer EH, et al. Failure of penicillin in a newborn with congenital syphilis. JAMA 1970; 212:1345.</a></li><li><a class="nounderline abstract_t">Rawstron SA, Mehta S, Marcellino L, et al. Congenital syphilis and fluorescent treponemal antibody test reactivity after the age of 1 year. Sex Transm Dis 2001; 28:412.</a></li><li><a class="nounderline abstract_t">Singh AE, Guenette T, Gratrix J, et al. Seroreversion of treponemal tests in infants meeting canadian surveillance criteria for confirmed early congenital syphilis. Pediatr Infect Dis J 2013; 32:199.</a></li><li><a class="nounderline abstract_t">Chang SN, Chung KY, Lee MG, Lee JB. Seroreversion of the serological tests for syphilis in the newborns born to treated syphilitic mothers. Genitourin Med 1995; 71:68.</a></li><li><a class="nounderline abstract_t">Lago EG, Vaccari A, Fiori RM. Clinical features and follow-up of congenital syphilis. Sex Transm Dis 2013; 40:85.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Congenital syphilis - United States, 2003-2008. MMWR Morb Mortal Wkly Rep 2010; 59:413.</a></li><li><a class="nounderline abstract_t">Gust DA, Levine WC, St Louis ME, et al. Mortality associated with congenital syphilis in the United States, 1992-1998. Pediatrics 2002; 109:E79.</a></li><li><a class="nounderline abstract_t">PUTKONEN T. Does early treatment prevent dental changes in congenital syphilis? Acta Derm Venereol 1963; 43:240.</a></li><li><a class="nounderline abstract_t">Stamos JK, Rowley AH. Timely diagnosis of congenital infections. Pediatr Clin North Am 1994; 41:1017.</a></li><li><a class="nounderline abstract_t">OKSALA A. Interstitial keratitis after adequate penicillin therapy; a case report. Br J Vener Dis 1957; 33:113.</a></li><li><a class="nounderline abstract_t">Pavithran K. Acquired syphilis in a patient with late congenital syphilis. Sex Transm Dis 1987; 14:119.</a></li><li><a class="nounderline abstract_t">Coles FB, Hipp SS, Silberstein GS, Chen JH. Congenital syphilis surveillance in upstate New York, 1989-1992: implications for prevention and clinical management. J Infect Dis 1995; 171:732.</a></li><li><a class="nounderline abstract_t">Mascola L, Pelosi R, Blount JH, et al. Congenital syphilis. Why is it still occurring? JAMA 1984; 252:1719.</a></li><li><a class="nounderline abstract_t">Desenclos JC, Scaggs M, Wroten JE. Characteristics of mothers of live infants with congenital syphilis in Florida, 1987-1989. Am J Epidemiol 1992; 136:657.</a></li><li><a class="nounderline abstract_t">Webber MP, Lambert G, Bateman DA, Hauser WA. Maternal risk factors for congenital syphilis: a case-control study. Am J Epidemiol 1993; 137:415.</a></li><li><a class="nounderline abstract_t">Southwick KL, Guidry HM, Weldon MM, et al. An epidemic of congenital syphilis in Jefferson County, Texas, 1994-1995: inadequate prenatal syphilis testing after an outbreak in adults. Am J Public Health 1999; 89:557.</a></li><li><a class="nounderline abstract_t">Warner L, Rochat RW, Fichtner RR, et al. Missed opportunities for congenital syphilis prevention in an urban southeastern hospital. Sex Transm Dis 2001; 28:92.</a></li><li><a class="nounderline abstract_t">TUCKER HA, ROBINSON RC. Disappearance time of Treponema pallidum from lesions of early syphilis following administration of crystalline penicillin G. Bull Johns Hopkins Hosp 1947; 80:169.</a></li><li class="breakAll">The World Health Organization. The global elimination of congenital syphillis: Rationale and strategy for action. http://www.who.int/reproductivehealth/publications/rtis/9789241595858/en/ (Accessed on December 20, 2016).</li><li class="breakAll">The World Health Organization. Elimination of mother-to-child transmission (EMTCT) of HIV and syphilis: Global guidance on criteria and processes for validation. http://www.who.int/reproductivehealth/publications/rtis/9789241505888/en/ (Accessed on December 20, 2016).</li><li><a class="nounderline abstract_t">Kiarie J, Mishra CK, Temmerman M, Newman L. Accelerating the dual elimination of mother-to-child transmission of syphilis and HIV: Why now? Int J Gynaecol Obstet 2015; 130 Suppl 1:S1.</a></li></ol></div><div id="topicVersionRevision">Topic 15400 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://ndc.services.cdc.gov/case-definitions/syphilis-2018/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevention. Syphilis (Treponema pallidum) 2018 Case Definition. https://ndc.services.cdc.gov/case-definitions/syphilis-2018/ (Accessed on June 17, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32497029" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Missed Opportunities for Prevention of Congenital Syphilis - United States, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sexually transmitted diseases treatment guidelines, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sexually transmitted diseases treatment guidelines, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sexually transmitted diseases treatment guidelines, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3696844" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Failure of benzathine penicillin G treatment in early congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Childhood syphilis in North Carolina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682315" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Congenital syphilis in neonates with nonreactive nontreponemal test results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9916946" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy of treatment for syphilis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9785110" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Congenital syphilis after treatment of maternal syphilis with a penicillin regimen exceeding CDC guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904625" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Congenital syphilis after maternal treatment for syphilis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116709" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epidemic syphilis: maternal factors associated with congenital infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063317" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Single-dose benzathine penicillin in infants at risk of congenital syphilis--results of a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8071762" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of asymptomatic congenital syphilis: benzathine versus procaine penicillin G therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2964810" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : In vitro culture system to determine MICs and MBCs of antimicrobial agents against Treponema pallidum subsp. pallidum (Nichols strain).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/789927" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Persistence of Treponema pallidum following penicillin G therapy. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210105" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Syphilis in children: congenital and acquired.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13364287" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Jarisch-Herxheimer reaction following penicillin treatment of early congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13364287" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Jarisch-Herxheimer reaction following penicillin treatment of early congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2174081" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation and treatment of congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6658628" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Congenital syphilis: a proposal for improved surveillance, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189610" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early Childhood Neurodevelopmental Outcomes in Infants Exposed to Infectious Syphilis In Utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4910820" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Failure of penicillin in a newborn with congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11460026" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Congenital syphilis and fluorescent treponemal antibody test reactivity after the age of 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22976052" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Seroreversion of treponemal tests in infants meeting canadian surveillance criteria for confirmed early congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7744415" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Seroreversion of the serological tests for syphilis in the newborns born to treated syphilitic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324972" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical features and follow-up of congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395934" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Congenital syphilis - United States, 2003-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986485" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mortality associated with congenital syphilis in the United States, 1992-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13972609" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Does early treatment prevent dental changes in congenital syphilis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936771" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Timely diagnosis of congenital infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13446428" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Interstitial keratitis after adequate penicillin therapy; a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3616853" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acquired syphilis in a patient with late congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876630" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Congenital syphilis surveillance in upstate New York, 1989-1992: implications for prevention and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6471297" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Congenital syphilis. Why is it still occurring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442732" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Characteristics of mothers of live infants with congenital syphilis in Florida, 1987-1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460624" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Maternal risk factors for congenital syphilis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10191801" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An epidemic of congenital syphilis in Jefferson County, Texas, 1994-1995: inadequate prenatal syphilis testing after an outbreak in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234792" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Missed opportunities for congenital syphilis prevention in an urban southeastern hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20291305" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Disappearance time of Treponema pallidum from lesions of early syphilis following administration of crystalline penicillin G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20291305" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Disappearance time of Treponema pallidum from lesions of early syphilis following administration of crystalline penicillin G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20291305" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Disappearance time of Treponema pallidum from lesions of early syphilis following administration of crystalline penicillin G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096725" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Accelerating the dual elimination of mother-to-child transmission of syphilis and HIV: Why now?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
